NasdaqGS:SIEN

Stock Analysis Report

Executive Summary

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Sientra has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Sientra's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.4%

NasdaqGS:SIEN

1.2%

US Medical Equipment

0.9%

US Market


1 Year Return

-65.9%

NasdaqGS:SIEN

14.7%

US Medical Equipment

0.3%

US Market

SIEN underperformed the Medical Equipment industry which returned 14.5% over the past year.

SIEN underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

SIENIndustryMarket
7 Day-0.4%1.2%0.9%
30 Day17.3%0.9%-1.9%
90 Day0.1%10.9%1.6%
1 Year-65.9%-65.9%15.6%14.7%2.6%0.3%
3 Year-13.9%-13.9%68.0%62.8%41.0%31.8%
5 Yearn/a132.7%105.9%55.2%38.0%

Price Volatility Vs. Market

How volatile is Sientra's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sientra undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Sientra's share price is below the future cash flow value, and at a moderate discount (> 20%).

Sientra's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Sientra is loss making, we can't compare its value to the US Medical Equipment industry average.

Sientra is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Sientra, we can't assess if its growth is good value.


Price Based on Value of Assets

Sientra is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Sientra expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

42.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Sientra's revenue is expected to grow significantly at over 20% yearly.

Sientra's earnings are expected to grow significantly at over 20% yearly.

Sientra's revenue growth is expected to exceed the United States of America market average.

Sientra's earnings growth is expected to exceed the United States of America market average.

Sientra's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Sientra will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Sientra performed over the past 5 years?

-38.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sientra does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Sientra's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Sientra's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Sientra has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Sientra has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Sientra improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Sientra's financial position?


Financial Position Analysis

Sientra is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sientra's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Sientra's level of debt (33.9%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (110.4% vs 33.9% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Sientra has sufficient cash runway for 1.9 years based on current free cash flow.

Sientra has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 28.5% each year.


Next Steps

Dividend

What is Sientra's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Sientra's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Sientra's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Sientra has not reported any payouts.

Unable to verify if Sientra's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Sientra has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Sientra's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Jeff Nugent (72yo)

3.8yrs

Tenure

US$2,997,871

Compensation

Mr. Jeffrey M. Nugent, also known as Jeff, has been the Chairman and Chief Executive Officer at Sientra, Inc. since November 12, 2015. Mr. Nugent has been a Director of Sientra, Inc. since July 2014. He se ...


CEO Compensation Analysis

Jeff's remuneration is higher than average for companies of similar size in United States of America.

Jeff's compensation has increased whilst company is loss making.


Management Age and Tenure

1.2yrs

Average Tenure

55yo

Average Age

The average tenure for the Sientra management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.1yrs

Average Tenure

63yo

Average Age

The tenure for the Sientra board of directors is about average.


Insider Trading

More shares have been bought than sold by Sientra individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$99,99811 Jun 19
Paul Little
EntityIndividual
Role
Chief Financial Officer
CFO, Senior VP & Treasurer
Shares17,391
Max PriceUS$5.75
BuyUS$50,00211 Jun 19
Kevin O'Boyle
EntityIndividual
Role
Member of the Board of Directors
Director
Shares8,696
Max PriceUS$5.75
BuyUS$119,99711 Jun 19
Keith Sullivan
EntityIndividual
Role
Member of the Board of Directors
Director & Advisor to MiraDry Business
Shares20,869
Max PriceUS$5.75
BuyUS$49,999,99911 Jan 19
Clarus Ventures, LLC
EntityCompany
Shares2,730,765
Max PriceUS$18.31
SellUS$46,11506 Sep 18
Jeffrey Nugent
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares1,852
Max PriceUS$24.90

Ownership Breakdown


Management Team

  • Jeff Nugent (72yo)

    Chairman & CEO

    • Tenure: 3.8yrs
    • Compensation: US$3.00m
  • Charles Huiner (48yo)

    COO and Senior VP of Corporate Development & Strategy

    • Tenure: 3.6yrs
    • Compensation: US$1.29m
  • Valerie Miller (55yo)

    VP & Corporate Controller

    • Tenure: 1.4yrs
  • Keith Sullivan (61yo)

    Director & Advisor to MiraDry Business

    • Tenure: 2.0yrs
    • Compensation: US$1.40m
  • Deborah Bettencourt

    Vice President of Customer Experience & Corporate Administration

    • Tenure: 0.0yrs
  • Neil Bhalodkar

    Senior Director of Investor Relations and Business Analytics

    • Tenure: 0.8yrs
  • Jason O’Hearn

    Vice President of Sales & Professional Relations

    • Tenure: 0.0yrs
  • Paul Little (54yo)

    CFO, Senior VP & Treasurer

    • Tenure: 1.0yrs
    • Compensation: US$1.59m
  • Oliver Bennett

    General Counsel and VP of Compliance & Legal

    • Tenure: 1.6yrs
  • Jane Wolf

    Vice President of Marketing

    • Tenure: 0.7yrs

Board Members

  • Jeff Nugent (72yo)

    Chairman & CEO

    • Tenure: 3.8yrs
    • Compensation: US$3.00m
  • Nick Simon (65yo)

    Lead Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$197.51k
  • Kevin O'Boyle (63yo)

    Director

    • Tenure: 5.1yrs
    • Compensation: US$188.76k
  • Keith Sullivan (61yo)

    Director & Advisor to MiraDry Business

    • Tenure: 2.0yrs
    • Compensation: US$1.40m
  • Philippe Schaison (57yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$296.26k
  • Mary Fisher

    Director

    • Tenure: 0.6yrs

Company Information

Sientra, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sientra, Inc.
  • Ticker: SIEN
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$340.112m
  • Shares outstanding: 49.29m
  • Website: https://sientra.com

Number of Employees


Location

  • Sientra, Inc.
  • 420 South Fairview Avenue
  • Suite 200
  • Santa Barbara
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
S0ZDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:39
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.